CVRXNMSHealthcare·Medical Devices#70 in industry

CVRx, Inc.

Reports in 14d· 2026-05-11

+1.5% · 90d

$7.65

-0.07 (-0.91%)

After-Hours $7.65(+0.00)

News

(1)

April 2026

Apr 20, 20261 week agoDEF 14AHealthcare

CVRx files proxy detailing 2026 governance and board votes

CVRXCVRx, Inc.

# 📜 What This Document Is 📄 This document is a Definitive Proxy Statement for the 2026 Annual Meeting of Stockholders. Think of it as a comprehensive playbook, designed to explain exactly how the company is governed and asking shareholders for their votes. It outlines the annual meeting logistics,

Read summaryView on SEC EDGAR

Key Data

Market Cap$201.3M

Open$7.71

Prev Close$7.72

Day Range$7.63 – $7.96

52W Range$4.30 – $11.30

Volume96,657

P/E (TTM)—

EPS$-2.04

Dividend Yield—

Beta1.12

Profit Margin-94.10%

Revenue Growth4.40%

Price Target$11.17(+46.0%)

Next Earnings2026-05-11(14d)

Analyst Ratings

Strong Buy7 analysts

Buy 6Hold 0Sell 1

About

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Healthcare · Medical Devices

223 employees

www.cvrx.com